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Generalized epilepsyObjectives: Using an adult cohort of patients with generalized epilepsy, we aimed to identify risk factors for de-
velopment of drug-resistant epilepsy (DRE), which if identiﬁable would allow patients to receive earlier treat-
ment and more speciﬁcally individualized treatment plans.
Methods: For the case–control study, 118 patients with generalized epilepsy (GE) between the ages of 18 and 75
were included after selection fromadatabase of 800 patients referred from throughout the SaskatchewanEpilep-
sy Program. Deﬁnitions were used in accordance with ILAE criteria. The odds ratio and its conﬁdence interval
were calculated. We performed a logistic regression analysis.
Results: Forty-four (37%) patients fulﬁlled the deﬁnition of DRE (cases), and seizures in 74 (63%) patients were
not intractable (controls). Patients with DREwere signiﬁcantly younger than the controls at the onset of epilepsy
(6.6 vs. 18.8 years, p = b0.001). Signiﬁcant variables on univariate analysis were the following: epilepsy diag-
nosed prior to 12 years (OR: 12.1, CI: 4.8–29.9, p b 0.001), previous history of status epilepticus (OR: 15.1, CI:
3.2–70.9, p b 0.001), developmental delay (OR: 12.6, CI: 4.9–32, p b 0.001), and cryptogenic epilepsy (OR:
10.5, CI: 3.9–27.8, p b 0.001). Our study showed some protective factors for DRE such as a good response to
ﬁrst AED, idiopathic etiology, and history of febrile seizures. In the logistic regression analysis, two variables
remained statistically signiﬁcant: developmental delay and more than one seizure type.
Conclusion: Our study has identiﬁed a set of variables that predict DRE in patients with generalized epilepsy. Risk
factors identiﬁed in our study are similar to those previously identiﬁed in pediatric studies, however, our study is
speciﬁcally tailored to adult patients with generalized epilepsy.
Published by Elsevier Inc.1. Background
It is estimated that seizures in 6% to 69% of patients fail to respond to
standard medical and surgical therapies and therefore these patients to
experience debilitating refractory seizures [1,2]. They are classiﬁed as
having drug-resistant epilepsy (DRE), a diagnosis with poor prognostic
implications such as higher rates of premature death, injuries, psycho-
social dysfunction, and reduced quality of life [3]. The early identiﬁca-
tion of patients with DRE would enable clinicians to more effectively
strategize treatment plans for these often complex cases.
The 2010 International League Against Epilepsy (ILAE) task force
deﬁned DRE as “failure of adequate trials of two tolerated and appropri-
ately chosen and used antiepileptic drugs (AED) schedules (whether as
monotherapies or in combination) to achieve sustained seizure free-
dom” [3]. Seizure freedom is deﬁned as at least three times the duration
of the longest interseizure interval prior to starting a new intervention.
Patients must be observed for at least 12 months to determine this, Division of Neurology, Royal
k.ca (J.F. Téllez-Zenteno).period. If no interseizure interval has been previously identiﬁed, seizure
freedom should be deﬁned as at least 12 months.
In this study, we explored risk factors for medically intractable
generalized epilepsy in an adult population. The majority of the litera-
ture surrounding medical intractability in patients with generalized
and focal epilepsy is based on pediatric populations [4]. However, a
few studies were identiﬁed as being aimed at an adult population.
Mohanraj [5] found that a history of febrile seizures was the only factor
contributing to treatment failure. Nicolson et al. [6] studied a population
of both pediatric and adult patientswith idiopathic generalized epilepsy
and found that atypical presentation (deﬁned as onset younger than
3 years or older than 20 years or with an atypical seizure type [absence
or myoclonic]) had a signiﬁcantly worse prognosis than those who did
not. Fernando-Dongas et al. [7] found that patients with valproic acid
(VPA)-refractory JMEweremore likely to have EEG asymmetry, atypical
seizure characteristics, and intellectual difﬁculty. Cutting and Gelisse [8]
reported a positive relation between psychological complications and
DRE. Benjamin et al. [9] found that drug resistance was a feature of pa-
tients with a higher frequency of spike–wave discharges on their EEGs.
Our objective was the identiﬁcation of risk factors associated with
DRE in adult patients with generalized epilepsy in the setting of a
Table 1
Analysis of continuous variables.
No DRE n=74
(mean, SD)
DRE n=44
(mean, SD)
p value
Age (years) 33.6 ± 12.7 30.5 ± 13.7 0.21
Age at onset (years) 18.8 ± 11.1 6.6 ± 6.9 b0.001
Years of evolution 14.7 ± 13.1 24.1 ± 13.5 b0.001
Number of status epilepticus events 1 ± 0 3.4 ± 3.7 0.39
Number of AEDs 2.6 ± 1.8 5.9 ± 2.2 b0.001
Number of seizures per month 2.6 ± 9.5 28.1 ± 93.6 0.09
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seizures are assessed.
2. Methods
2.1. Population and type of study
We included patients between the ages of 18 and 75 who had been
previously diagnosed with generalized epilepsy and followed up by the
treating epileptologist. These patients were recruited from a single
center where two treating epileptologists have collected a database of
800 patients with epilepsy from a catchment area of 1.1 million people.
The center has an epilepsy program that serves the whole province of
Saskatchewan, and it is the only center that provides epilepsy surgery.
The center receives and follows complex cases but also assesses patients
with new onset epilepsy. We used a case–control study methodology.
Diagnoses and deﬁnitions were used in accordance with the 1985 ILAE
criteria [10], and we used the current deﬁnition of DRE by the ILAE [3].
Patientswhomet the criteria for DRE according to the ILAE classiﬁcation
were classiﬁed as cases. The control group was formed with patients
who did not fulﬁll the new deﬁnition of DRE. The diagnosis of general-
ized epilepsy was determined on clinical grounds with EEG conﬁrma-
tion in all cases and followed the criteria of the ILAE. We calculated a
sample size using the variable developmental delay with the following
parameters (case proportion = 49%, control proportion = 4, power
0.80, alpha 0.05), and we needed at least 53 cases and 53 controls
[11]. We included all the available cases and controls in our database
in order to have at least one case and two controls. We believe that
being the sole center in the province is an advantage for this study,
having the opportunity to have a adequate number of cases in addition
to having controls from the same geographical area. The project was
reviewed and approved by the Research Ethics Board (REB) of the
University of Saskatchewan.
2.2. Variables and deﬁnitions
We gathered the following information from the charts: socio-
demographic characteristics, characteristics of epilepsy, treatment, di-
agnostic tests, and risk factors for DRE. The entire patient database
was analyzed and cataloguedwith the use of a collection sheet. Each pa-
tient database collected information about the individual's general de-
mographics (age, gender, education level, occupation, marital status,
number of children, substance history), seizure history (initial seizure
frequency, age at diagnosis and years of evolution, presence of neonatal
seizures, febrile seizures or status epilepticus, frequency of seizures at
the time of evaluation, ﬁrst AED used, response to ﬁrst AED [good or
bad], family history of epilepsy, comorbid conditions, neurological
abnormalities on examination, presence of developmental delay (DD)
(mild, severe, profound) or autism, and comorbid psychiatric condi-
tions, i.e., depression, psychosis, behavioral problems, and anxiety
and/or panic attacks). Speciﬁc information regarding the etiology of ep-
ilepsy was also collected: whether epilepsy was idiopathic, genetic, or
cryptogenic; if perinatal insults were sustained (i.e., asphyxia during
birth, pregnancy complication, or intrauterine viral infections were doc-
umented); history of cranial trauma, cerebral neoplasm (malignant or
benign), metabolic disorders, cerebrovascular accidents, cerebral infec-
tion, presence of cortical dysplasia ormesial temporal sclerosis, etc. Spe-
ciﬁc seizure proﬁles were documented and catalogued according to the
ILAE coding (IIA–F, III, IV). Proﬁles included absence, myoclonic, clonic,
tonic, tonic–clonic, and atonic seizures. Unclassiﬁable seizures were
classiﬁed as III, and seizures too frequent to distinguish individual sei-
zures were classiﬁed as IV.
Epileptic syndromes were identiﬁed according to the ILAE deﬁni-
tion [10]. Idiopathic syndromes are generally thought to arise from ge-
netic abnormalities that lead to alteration of basic neuronal regulation.
Symptomatic epilepsy is deﬁned as epilepsy that arises from the effectsof an epileptic lesion,whether that lesion is focal (i.e., tumor), or a defect
in metabolism causingwidespread injury to the brain. Cryptogenic syn-
dromes involve a presumptive lesion that is otherwise difﬁcult or im-
possible to uncover during evaluation. After deﬁning each patient's
syndrome and seizure proﬁle, speciﬁc epileptic syndromes were docu-
mented, including West syndrome, Lennox–Gastout syndrome, child-
hood absence epilepsy (CAE), juvenile myoclonic epilepsy (JME),
mitochondrial disease, Rasmussen encephalitis, mesial temporal sclero-
sis (MTS), or others. All relevant investigationswere included in the da-
tabase collection sheets, including routine and ambulatory EEG and
results, video EEG telemetry data, imaging results, including CT, MRI,
and PET scans, history of epilepsy surgeries and outcome, and any
neuropathology ﬁndings. Finally, a detailed history of AED use was
taken, including the following: dose, frequency, reasons for discontinu-
ation (adverse effect, unsatisfactory control, long-term seizure freedom,
psychosocial concerns, i.e., pregnancy, administrative reasons, i.e., lost
to follow-up, ﬁnancial issues, patient/caretaker preference, others),
and outcome dimension. Other therapies were documented, including
ketogenic diet and vagal nerve stimulation. Developmental delay was
classiﬁed using the DSM-IV criteria as follows: Mild DD (IQ: 50–75,
often academic skills up to the 6th level, self-sufﬁcient), moderate DD
(IQ: 35–55, carry out work and self-care task with moderate supervi-
sion, live within a community), severe DD (IQ: 20–40, master very
basic self-care skills and some communication, live in group home),
and profound DD (IQ b 20–25, may develop basic self-care and commu-
nication skills).
2.3. Statistical analysis
We used descriptive statistics to assess frequencies and distri-
butions. As appropriate, numerical and categorical data were compared
with either T-test or Chi-squared test. We calculated odds ratios and
corresponding conﬁdence intervals. We also performed a logistic re-
gression analysis of the most signiﬁcant risk factors.
3. Results
3.1. General description
One hundred eighteen patients with generalized epilepsy were in-
cluded. Seventy-one (60%) were males, and 47 (40%) were females.
The mean age at onset of epilepsy was 14.2 ± 11.4 (range: 0–55). The
mean age of patients was 32.5 ± 13.1 (range: 18–75). The mean num-
ber of years of evolution of the epilepsy was 18.2 ± 13.9 (range: 0–
70). Overall, forty-four (37%) patients fulﬁlled the deﬁnition of DRE
(cases) and seventy-four (63%) patients did not have DRE (controls).
Sixty-two percent of patients in our study started having seizures in
childhood (younger than 16 years).
3.2. Comparison of numerical variables between cases and controls
Patients with DRE were signiﬁcantly younger than the controls
at the onset of epilepsy (6.6 vs. 18.8, p b 0.001), had more years of evo-
lution (24.1 vs. 14.7, p b 0.001), and had usedmore AEDs (5.9 vs.2.6, p b
0.001). See Table 1.
Table 3
Analysis of categorical variables (protective factors on the univariate analysis).
Prognostic factor No DRE
n=74
DRE
n=44
OR CI p value
History of febrile seizures 0 (0) 3 (6.8) 0.36 0.28–0.46 0.02
Unknown etiology 68 (91.9) 34 (7.3) 0.30 0.10–0.90 0.03
Idiopathic epilepsy 65 (87.8) 13 (29.5) 0.05 0.02–0.15 b0.001
Good response to ﬁrst AED 44 (73.3) 6 (35.3) 0.10 0.04–0.28 b0.001
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The following variables were identiﬁed as risk factors: age at onset
of epilepsy b12 years (OR: 12.1, CI: 4.8–29.9, p b 0.001), presence of
developmental delay (OR: 12.6, CI: 4.9–32, p b 0.001), autism (OR: 5.7,
CI: 1.0–29.5, p b 0.02), cryptogenic epilepsy (OR: 10.5, CI: 3.9–27.8,
p b 0.001), more than one seizure type (OR: 28.4, CI: 8.9–90, p b
0.001), history of status epilepticus (OR: 15.1, CI: 3.2–70.9, p b
0.001), Lenox–Gastaut syndrome (OR: 37.8, CI: 4.7–299, p b 0.001),
any epileptic syndrome (OR: 9.50, CI: 3.7–23.7, p b 0.001), more than
one seizure per month (OR: 10.6, CI: 3.3–34.7, p b 0.001). Other vari-
ables are displayed in Tables 2 and 4.
3.4. Protective factors for drug-resistant epilepsy
The following variables were identiﬁed as protectors against DRE:
good response to ﬁrst AED (OR: 0.10, CI: 0.04–0.28, p b 0.001), history
of febrile seizures (OR: 0.36, CI: 0.28–0.46, p 0.02), unknown etiology
(OR: 0.30, CI: 0.10–0.90, p 0.03), and idiopathic epilepsy (OR: 0.05, CI:
0.02–0.15, p b 0.001). See Table 3.
3.5. Multivariate analysis
We performed a forward stepwise logistic regression analysis.
The following signiﬁcant variables were included: status epilepticus,
presence of developmental delay, more than one seizure type,
cryptogenic syndrome, age at onset of epilepsy b12 years, epileptic
syndrome (i.e., Lennox–Gastaut), and frequent spike–waves in the
ﬁrst diagnostic EEG. In ourmodel, two variables remained statistical-
ly signiﬁcant. The presence of developmental delay (OR: 9.02, CI: 2.56–
31.71, p 0.001) and more than one seizure proﬁle (OR: 26.5, CI: 8.07–
85.35, p b 0.001) remained statistically signiﬁcant in the multivariate
analysis.
4. Discussion
The risk factors for drug-resistant generalized epilepsy identiﬁed in
our study are similar to the ones identiﬁed in pediatric populations.
Our results could be expected since a large percentage of our patients
were initially diagnosed at a young age (mean: 18.8 ± 11 years) and,
therefore, carry over risk factors from the pediatric population to the
adult population as they ‘growwith epilepsy’. It is difﬁcult to generalize
risk factors across adult and pediatric populations as etiologies may dif-
fer, and adults are subject to different environmental exposures.
To our knowledge, this is the ﬁrst case–control study using the ILAE
deﬁnition of DRE,which has been validated recently [12]. Pediatric stud-
ies assessing drug-resistant epilepsy have used different deﬁnitions.
Berg [1] deﬁned DRE in pediatric populations as failure or lack of seizure
control with more than 2 ﬁrst-line antiepileptic drugs with an averageTable 2
Analysis of categorical variables (risk factors on the univariate analysis).
Prognostic factor No DRE n=74
Age at onset of epilepsy ≤12 years 18 (24)
Presence of developmental delay 9 (12.2)
Autism 2 (2.7)
Symptomatic epilepsy 2 (2.7)
Cryptogenic epilepsy 7 (9.5)
Frequent spike–waves in ﬁrst diagnostic EEG 18 (27.7)
More than 1 seizure type 19 (26.0)
Status epilepticus 2 (3)
Lennox–Gastaut syndrome 1 (1.4)
Any epileptic syndrome 9 (12.2)
More than 1 seizure per month 5 (18)
Good response to AED 44 (73.3)
EEG slowing 8 (11.0)of no more than 1 seizure per month for 18 months and more than 3
consecutive months seizure-free during that interval. Kwan and Brodie
[13] used a deﬁnition that considered both pediatric and adult patients
who had seizures and, by deﬁnition, were considered to have refractory
epilepsy. Seizure-free status was deﬁned as the lack of seizures of any
type for a minimum of 1 year while receiving the same dose of AEDs
orwhile not taking anymedication. Camﬁeld et al. [14] deﬁned intracta-
ble epilepsy as an average of at least one seizure every 2 months in the
ﬁrst ﬁve years of treatment. They deﬁned intractable epilepsy with
more than ﬁve years of treatment as at least one seizure per year. Ac-
cording to a recent article, all these deﬁnitions are valid, although the
deﬁnition of the ILAE that we used in our study has the higher inter
and intracorrelation rates [12].
The ﬁnding that developmental delay was predictive for drug resis-
tance in generalized epilepsy is one of the most salient observations in
our study. This ﬁnding has been demonstrated in previous studies,
and it is one of the most reported factors in pediatric populations [15,
16]. Some studies have shown that epilepsy ismore common in patients
with developmental delay than the general population, supporting the
ﬁnding that developmental delay is a clear isolated risk factor for epilep-
sy. We believe that our observation is signiﬁcant as developmental
delay remained as an important risk factor in the multivariate analysis,
independent of syndromes such as Lennox–Gastaut. On the other hand,
developmental delay could be part of some epilepsy syndromes, such as
Lennox–Gastaut syndrome, which is characterized by medical refracto-
riness; therefore, developmental delay probably implies a more diffuse
and severe brain injury. As was expected, the presence of Lennox–
Gastaut syndromewas associatedwith DRE in our study. This is not sur-
prising considering that several studies have shown this association
[17].
The need for early identiﬁcation of DRE iswell recognized andwould
allow physicians to initiate more aggressive forms of treatment without
being obliged to wait for the progression of the disease to declare itself
over time. Several ways of predicting this may be possible, including ge-
netic analysis, neuroimaging techniques, epidemiological data analysis,
and syndromic classiﬁcation. Arroyo et al. [18] found that using
syndromic classiﬁcation, especially in the case of highly refractory epi-
lepsies, provided a better approach than the aforementioned tech-
niques. However, they did not feel that they were as useful in partialDRE n=44 OR 95% conﬁdence
interval
p value
35 (80) 12.1 4.8–29.9 b0.001
28 (63.6) 12.6 4.9–32.0 b0.001
6 (13.6) 5.7 1.0–29.5 0.02
8 (18.2) 8.0 1.6–39.6 0.004
23 (52) 10.5 3.9–27.8 b0.001
22 (56.4) 3.3 1.4–7.7 0.004
40 (90.9) 28.4 8.9–90.0 b0.001
13 (29.5) 15.1 3.2–70.9 b0.001
15 (34.1) 37.8 4.7–299.0 b0.001
25 (56.8) 9.5 3.7–23.7 b0.001
29 (71) 10.6 3.3–34.7 b0.001
6 (35.3) 0.20 0.63–0.625 0.04
11 (25.0) 2.7 0.99–7.38 0.05
Table 4
Other explored variables that were nonstatistically signiﬁcant.
Prognostic factor No DRE (%)
n=77
DRE (%)
n=44
OR 95% conﬁdence
interval
p value
Male 44 (37.3) 27 (22.9) 1.05 0.65–1.70 0.84
Neonatal seizures 3 (4.1) 6 (13.6) 3.74 0.89–15.19 0.06
Family history of epilepsy (immediate family) 12 (16.4) 8 (18.2) 1.13 0.42–3.02 0.81
Remote family history of seizures 18 (24.7) 7 (15.9) 0.58 0.22–1.52 0.26
Any family history of epilepsy 28 (38.4) 14 (31.8) 0.75 0.34–1.65 0.48
Profound developmental delay 3 (33.3) 9 (32.1) 0.95 0.19–4.68 0.95
Asphyxia (etiology) 1 (1.4) 3 (6.8) 5.34 0.54–53.03 0.11
Psychiatric diagnosis (any) 13 (17.6) 8 (18.2) 1.04 0.39–2.76 0.93
Depression 5 (6.8) 0 (0) 0.61 0.53–0.71 0.08
Psychosis 1 (1.4) 2 (4.5) 3.48 0.31–39.50 0.29
Anxiety 1 (1.4) 0 (0) 0.62 0.54–0.72 0.44
Panic attacks 0 (0) 1 (2.3) 0.37 0.29–0.47 0.19
Severe developmental delay 2 (22.2) 12 (42.9) 2.63 0.46–14.97 0.27
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dictable in some well-deﬁned pediatric epilepsy syndromes, such as
neonatal Ohtahara syndrome, West syndrome, and severe myoclonic
epilepsy in infants, myoclonic–astatic epilepsy, Lennox–Gastaut syn-
drome, Rasmussen encephalitis, and partial epilepsies secondary to cor-
tical dysplasia [18]. Our study supports the approach of Arroyo in adult
populations. Our analysis shows that patients with cryptogenic and
symptomatic epilepsy had a signiﬁcantly higher risk of developing
DRE than patients with idiopathic epilepsy as previous studies in pedi-
atric populations have shown [18,19]. Our study supports the notion
that the early classiﬁcation of the syndrome can help not only to distin-
guish different groups of patients taking into account the etiology but
also to potentially identify patients who will potentially develop DRE
in the future. In a similar direction, our study shows that the presence
of abnormality in neuroimaging (symptomatic epilepsy) was a predic-
tor for DRE as pediatric studies have shown [12,15,20].
We found that more than one seizure per month was a signiﬁcant
factor to develop drug resistance on univariate analysis. This observa-
tion ﬁts with what has been previously found in pediatric studies.
Camﬁeld et al. [20] reported that children treated aftermultiple seizures
(N10) had a lower rate of long-term remission than those treated earlier
andmore commonly were younger at onset of epilepsy and with a high
prevalence of complex partial seizures. Overall population-based stud-
ies and systematic reviews indicate that early onset of epilepsy and pre-
treatment high-frequency seizures are more likely associated with a
poor prognosis [21,22].
Our study showed some factors that decreased the risk for DRE, such
as a good response to ﬁrst AED, idiopathic etiology, and history of febrile
seizures. These variables did not survive multivariate analysis. The ﬁrst
of these variables intuitively makes sense. Those patients who respond
well to the ﬁrst AED likely will not go on to meet the deﬁnition of DRE.
This protective factor has been demonstrated in several publications,
and it is consistent in adult and pediatric populations but also consistent
in cohorts of focal and generalized epilepsies [23,24]. Likewise, idio-
pathic generalized epilepsy is classically thought of as a relatively be-
nign condition, and close to 70–80% or more of patients who are
diagnosed with IGE respond well to medication [25]. Our study shows
88% of patients with idiopathic generalized epilepsy did not have DRE
and it was a protective factor in the univariate analysis (OR: 0.05, CI:
0.02–0.15, p b 0.001). The presence of febrile seizures leading to DRE
has been controversial in the literature, and some studies demonstrate
a protective effect, and others negate this. In our particular study popu-
lation, febrile seizure history seemed to be protective towards drug
resistance.
4.1. Limitations
Our study has some limitations. It is a retrospective study, which
classiﬁes patients at only one point in their history. It may be thatevolution of drug resistance occurs after the point at which we identi-
ﬁed them. We hope to rectify this by conducting a large cohort trial in
the future, examining these variables with the validated deﬁnition of
DRE. Our study has many strengths — it was conducted at a single cen-
ter, which acts as a referral center for a population of 1.1 million people.
The database for two treating epileptologists is comprehensive. We
used a standardized, validated deﬁnition of drug resistance from the
ILAE. In addition, our methodology and analysis are strong. Finally, an
important limitation in our study is the inclusion of patientswho started
with epilepsy since childhood and patients with adult onset. Our analy-
sis may be biased with the inclusion of both groups, although our main
objective was exploration of risk factors in a standard adult epilepsy
clinic where a combination of seizure onsets is commonly seen. In the
future, we will only explore patients with adult onset as the risk factors
could be different.
4.2. Conclusions
Our study suggests that signiﬁcant risk factors for drug-resistant
generalized epilepsy aremore than one seizure type and presence of de-
velopmental delay. These results can help adult epileptologists to iden-
tify patients with a diagnosis of generalized epilepsy that are at risk for
DRE. This will allow identiﬁed patients to receive earlier treatment and
more speciﬁcally individualized treatment plans: Epileptologists may
be more aggressive, earlier on, with potentially invasive therapies,
such as vagal nerve stimulation and epilepsy surgery for suitable candi-
dates. This may improve the patients' quality of life and help them to
avoid mortality and morbidity from a variety of factors including nega-
tive side effects resulting from multiple AEDs which are not providing
additional beneﬁts.
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